Orthofix International N.V. — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual filing, not a standalone fourth-quarter report. The issuer named in the filing is Orthofix International N.V.
Business context
Orthofix is a global medical-device company with four businesses: BioStim (bone-growth stimulation), Biologics (regenerative tissues), Extremity Fixation, and Spine Fixation. Products are distributed in more than 70 countries. BioStim represented 43% of 2016 sales, Extremity Fixation 25%, Spine Fixation 18%, and Biologics 14%.
Financial performance and liquidity
- Revenue: $409.8 million, up 3.4% from $396.5 million in 2015 (up 4.0% at constant currency). Gross profit was $321.9 million; gross margin rose to 78.6% from 78.2%.
- Operating results: Operating income was $21.1 million, versus $9.3 million in 2015; operating margin was 5.1%. The company reported continuing-operations income of $3.5 million, compared with a $2.3 million loss, and total net income of $3.1 million versus a $2.8 million loss. Diluted EPS was $0.17.
- Fourth quarter: Sales were $108.5 million, compared with $104.6 million in Q4 2015. Operating income was $7.4 million; continuing-operations loss was $5.1 million and net loss was $3.2 million.
- Segment sales: BioStim increased 7.0% to $176.6 million; Extremity Fixation increased 6.9% to $102.7 million (9.6% constant currency). Biologics fell 3.2% to $57.9 million and Spine Fixation fell 4.0% to $72.6 million.
- Costs and unusual charges: General and administrative expense declined 14.6% to $74.4 million, while R&D rose 9.1% to $28.8 million. Operating results included $14.4 million of charges related to U.S. government resolutions and $2.0 million of restatement-related costs. The company also recorded a $2.7 million other-than-temporary impairment on its eNeura debt security.
- Cash flow: Operating cash flow was $44.7 million, versus $43.6 million. Capital expenditures were $18.3 million and reported free cash flow was $26.4 million, up from $15.7 million.
- Liquidity and debt: Cash and cash equivalents were $39.6 million, down from $63.7 million; a further $14.4 million was restricted in escrow for settlements. Current assets were $194.4 million and current liabilities $83.4 million. No borrowings were outstanding under the $125 million secured revolving facility; the company reported compliance with its financial covenants. Long-term debt was zero.
- Capital allocation: The company completed its $75 million repurchase authorization, buying 1.54 million shares for $63.4 million in 2016. It reported no history of dividends and no near-term intention to pay them.
Material changes, outlook and risks
- Management cited growth in BioStim and Extremity Fixation, improved gross margin, and lower G&A and prior-restatement costs. BioStim sales benefited from more prescribing physicians and improved order-to-cash collections. Biologics faced lower average selling prices and exclusion from a large hospital purchasing organization; Spine Fixation was affected by a similar exclusion and lost surgeon customers.
- The company completed Project Bluecore, a multi-year systems and controls initiative. Management said it had initiated a restructuring, primarily in Extremity Fixation, to reduce costs and wind down a non-core business. Total expected pretax restructuring expense was about $3.0 million across 2016 and 2017; $2.0 million was recorded in 2016.
- In January 2017, the company announced FDA and European CE approval of next-generation spinal and cervical stimulators. NASS coverage recommendations issued in late 2016 supported electrical stimulation as an adjunct to spinal fusion. These developments are potential access and adoption supports, not quantified financial guidance.
- Guidance: The filing provides no specific revenue or earnings forecast. Management expected 2017 capital expenditures of $13 million to $16 million.
- Legal and compliance: In January 2017, the SEC approved settlements concerning prior accounting restatements and alleged improper payments in Brazil; $14.4 million had been accrued and escrowed in 2016 and was released to the SEC. The company also remained subject to a five-year Corporate Integrity Agreement and related probation obligations. Noncompliance could lead to penalties or exclusion from federal healthcare programs.
- Other key risks: Reimbursement and pricing pressure, medical-device regulation and product liability, dependence on third-party manufacturers and MTF as the sole supplier of key allografts, foreign-exchange exposure, international anti-bribery compliance, and potential recovery risk on the $15 million eNeura note. The note’s year-end fair value was $12.2 million; its acquisition option expired without exercise.
- The company reported effective disclosure controls and internal control over financial reporting as of year-end; Ernst & Young issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether BioStim and Extremity Fixation growth can offset continuing weakness in Biologics and Spine Fixation, including the effects of pricing and purchasing-group access.
- Whether 2016 profitability is sustainable after the settlement charges, unusually high 81.6% effective tax rate, restructuring costs, and eNeura impairment.
- Cash available for operations after distinguishing unrestricted cash from the $14.4 million restricted settlement escrow, and the cash impact of repurchases and planned 2017 capital spending.
- Progress on the Extremity Fixation restructuring, next-generation stimulator adoption, and the expected benefits of NASS coverage recommendations.
- Recovery prospects for the eNeura note, compliance with the Corporate Integrity Agreement and probation, and exposure from remaining legal, tax, reimbursement, and product-liability matters.